Heparin-free veno-venous extracorporeal membrane oxygenation as a bridge therapy for airway interventions in malignant central airway obstruction: Case series and literature review.

Medicine (Baltimore)Sep 4, 2026

Siyu Yang, Zhenshun Cheng, Qing Liu et al.

✦ AI-curated · Sources linked

Case in brief

Three patients with malignant central airway obstruction (MCAO) presented with severe respiratory failure due to bronchial obstruction from tumors. Conventional intubation was ineffective, leading to the initiation of heparin-free veno-venous extracorporeal membrane oxygenation (VV-ECMO) for gas exchange support. Following ECMO, all patients underwent successful airway interventions, resulting in immediate improvement in oxygenation.

Diagnostic / clinical pearl

VV-ECMO can be an effective bridge therapy for patients with MCAO undergoing high-risk airway interventions, particularly when traditional ventilation methods fail.

Why it matters

The use of a heparin-free protocol during VV-ECMO may provide a safe alternative for short-term support, highlighting the importance of tailored anticoagulation strategies in complex cases.

Source

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.